ESMO 2020: Trabectedin No Better Than Carboplatin When Combined With Pegylated Liposomal Doxorubicin for Recurrent Ovarian Cancer
Results of INOVATYON suggest platinum-based regimens remain the standard of care
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.